zentalis board of directors

Dr. Blackwell is a current member of Zentalis Board and previously served as Chief Medical Officer of Tempus Labs and held clinical development leadership roles at Eli Lilly and Company. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Zentalis Pharmaceuticals Announces the Appointment of Dr. Kimberly Blackwell to its Board of Directors. Non-employee members of the board of directors (the Board) of Zentalis Pharmaceuticals, Inc. (the Company) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this Program), as amended by the Board effective March 18, 2021 (the Effective Date).This Program has been adopted under the Companys 2020 Search Jobs; Connect With Us; Partners. Previously, she held increasing responsibility at Akebia Therapeutics, Inc., culminating in the role of vice president of legal. Dr. Blackwell has been an independent director of Zentalis since 2020. About Zentalis We are focused on the creation of differentiated small molecule treatments targeting fundamental biological pathways of cancer. Anthony Y. Medical Sector. USA, NY Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Dr Kimberly Blackwell to its Board of Directors. Posted on 07/01/2020 72 . USA, NY Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways in cancer, today announced the appointment of David Johnson to its Board of Directors. She brings extensive experience as a senior financial executive in the life sciences industry. The AP news staff was not involved in its creation. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Press release content from Business Wire. Zentalis Pharmaceuticals Announces the Appointment of Dr. Kimberly Blackwell to its Board of Directors. President and Director of Zentalis Pharmaceuticals. 734th out of 1,418 stocks. I would like to thank Pat Machado for his contributions to the Board and Roivant over the past six years . Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support 10835 Road to the Cure Suite 205 San Diego, CA 92121. Zentalis Pharmaceuticals is a New York City and San Diego based biotech company dedicated to the discovery and development of clinically differentiated small molecules targeting fundamental biological pathways of cancer. The Board of Directors of Zentalis Pharmaceuticals. 10275 Science Center Drive Suite 200 San Diego, CA 92121 For More Information. President and Director of Zentalis Pharmaceuticals. post or otherwise publish any content unrelated to the board or the board's topic. restrict or inhibit any other user from using the boards. NEW YORK and SAN DIEGO, July 01, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological Dr. Blackwell is a renowned breast cancer See the breakdown of the total annual compensation for Kimberly Blackwell for being a board member of ZENTALIS PHARMACEUTICALS INC, as well as other members of the Board of Directors for ZENTALIS PHARMACEUTICALS INC Company profile for Zentalis Pharmaceuticals Inc. including key executives, insider trading, ownership, revenue and average growth rates. Before Zentalis, Paul served as general counsel and corporate secretary at LogicBio Therapeutics, Inc. January 09, 2020 08:00 AM Eastern Standard Time. Jan 9, 2020 at 8:00 AM EST. Previously, she held increasing responsibility at Akebia Therapeutics, Inc., culminating in the role of vice president of legal. Previously, she held increasing responsibility at Akebia Therapeutics, Inc., culminating in the role of vice president of legal. For More Information. Non-employee members of the board of directors (the Board) of Zentalis Pharmaceuticals, Inc. (the Company) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this Program).This Program has been adopted under the Companys 2020 Incentive Award Plan (the Equity Plan) and shall be 1-212-433-3791 info@zentalis.com Item 5.02. Dr. Kariuki is a highly accomplished finance Zentalis provides equal employment opportunity to all employees and applicants without regard to an individuals protected status. Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Enoch Kariuki, PharmD, to its Board of Directors Before Zentalis, Paul served as general counsel and corporate secretary at LogicBio Therapeutics, Inc. Pharmaceutical Preparations Industry. Zentalis Pharmaceuticals Appoints David Johnson to Board of Directors Explore New York business news Jan 9 2020 BoardMoves Mr. Johnson is a veteran biopharmaceutical and healthcare leader with more than 25 years of experience in developing drugs and Notice to Search Firms/Third-Party Recruitment Agencies (Recruiters) The Human Resources team manages the recruitment and employment process for Zentalis Pharmaceuticals, Inc. (Zentalis) To protect the interest of all parties involved, Zentalis will only accept resumes from a recruiter if an executed search agreement is in place at the start of the recruitment effort. On May 10, 2022, | July 3, 2022 357th out of 679 stocks About Zentalis We are focused on the creation of differentiated small molecule treatments targeting fundamental biological pathways of cancer. Item 5.02. We are excited to welcome David to our board as he brings his

10835 Road to the Cure Suite 205 San Diego, CA 92121. The Board of Directors (the Board) of Zentalis Pharmaceuticals, Inc. (the Company) has adopted the following Corporate Governance Guidelines (the Guidelines) to assist the Board in the exercise of its responsibilities and to serve the interests of the Company and its stockholders. Before Zentalis, Paul served as general counsel and corporate secretary at LogicBio Therapeutics, Inc. Implicit in this philosophy is the importance of sound corporate governance. In addition, Board member Dave Johnson has been appointed Chairman.

Investors/Media Home Company Profile. Dr. Board of Directors in Zentalis Pharmaceuticals, Inc. For its 2020 fiscal year, Zentalis Pharmaceuticals, Inc., listed the following board members on its annual proxy statement to the SEC. He will report to Chief Executive Officer Dr. Kimberly Blackwell. Download PDF. Implicit in this philosophy is the importance of sound corporate governance.

Zentalis intends to use the net proceeds of the offering to help fund ongoing and planned clinical trials, including studies of ZN-c3, its Wee1 inhibitor, and ZN-d5, its BCL-2 inhibitor, and for working capital and general corporate purposes. Zentalis and Pfizer plan to jointly advance the clinical development of ZN-c3, a selective Wee1 inhibitor designed to induce synthetic lethality in cancer cells Adam Schayowitz, Ph.D., MBA, Vice President & Medicine Team Group Lead for Breast Cancer, Colorectal Cancer and Melanoma, Pfizer, to join Zentalis Scientific Advisory Board The Board of Directors of Zentalis Pharmaceuticals. On June 30, 2022, the Board of Directors (the "Board") of BioXcel Therapeutics, Inc. (the "Company") appointed Michael Miller to the Board, 65, has served as an advisor to pharmaceutical companies, Zentalis Pharmaceuticals, Inc. and Protagonist Therapeutics, Inc., since July 2021 and September 2020, respectively. Mr. Zentalis Pharmaceuticals (the Company or Zentalis), a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways in cancer, today announced the appointment of David Johnson to its Board of Directors. Item 5.02. Learn about the executive team and board of directors at Zentalis Pharmaceuticals Inc Ordinary Shares (ZNTL:XNAS) and review their bios and compensation over the latest fiscal years. Michelle Arthur Associate Director Pharmacovigilance at Zentalis Pharmaceuticals Somerville, New Jersey, United States 298 connections She brings extensive experience as a senior financial executive in the life sciences industry.

Zentalis Pharmaceuticals Appoints David Johnson to Board of Directors. I would like to thank Pat Machado for his contributions to the Board and Roivant over the past six years. Melissa Epperly has served as Chief Financial Officer at Zentalis Pharmaceuticals, Inc., a clinical-stage cancer company, since September 2019. Research and Business Development Partnerships Zentalis Pharmaceuticals Announces $25 Million Equity Investment from Pfizer. Zentalis Pharmaceuticals Announces the Appointment of Dr. Kimberly Blackwell to its Board of Directors /EIN News/ -- NEW YORK and SAN DIEGO, July 01, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological On June 21, 2022, Alexis M. Pinto notified Zentalis Pharmaceuticals, Inc. (the "Company") of her resignation as Chief Legal Officer and Secretary of the Company, effective as of July 5, 2022. Science Center. The Pfizer Board Policies Ensuring ethical leadership Corporate Governance FAQs Learn more about our approach Contact Our Directors Email any of our Directors History; Careers. Please contact us at bd@ null zentalis.com to discuss partnering and collaborations opportunities. Anthony has played an active role across the life science industry since 2002 and currently serves as President and Chief Executive Officer for Zentalis Pharmaceuticals. NEW YORK & SAN DIEGO Zentalis Pharmaceuticals (the Company or Zentalis), a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways in cancer, Sun serves as Chief Executive Officer and a member of the board of directors of Zentera, the Companys joint venture in China and Kalyra Pharmaceuticals, Inc., or Kalyra, a small molecule drug discovery and Dr Wollowick is the Sr. Director of Business Liked by Yelena Lalazar (Blumshtein) I was 17 years old when I was forced into an arranged marriage. On May 25, 2022, the Board of Directors (the "Board") of Zentalis Pharmaceuticals, Inc. (the "Company") appointed Cam S. Gallagher, a current Executive Director of the Company and a current member of the Board, as President of the Company, succeeding Kimberly Blackwell in such role, effective as of May 30, 2022 (the "Commencement Date"). 1-212-433-3791 info@zentalis.com On May 10, 2022, | July 3, 2022 (the "Company") sets high standards for the Company's employees, officers and directors. On May 25, 2022, the Board of Directors (the "Board") of Zentalis Pharmaceuticals, Inc. (the "Company") appointed Cam S. Gallagher, a current Executive Director of the Company and a current member of the Board, as President of the Company, succeeding Kimberly Blackwell in such role, effective as of May 30, 2022 (the "Commencement Date"). Corporate Governance Overview. Zentalis Pharmaceuticals (the Company or Zentalis), a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways in cancer, today announced the appointment of David Johnson to its Board of Directors. We are pleased to welcome Enoch to our Board of Directors, and believe his--Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical Gallagher, who previously served as an Executive Director of Zentalis, will remain a member of the Board of Directors, which he has served on since the Companys founding. On June 30, 2022, the Board of Directors (the "Board") of BioXcel Therapeutics, Inc. (the "Company") appointed Michael Miller to the Board, 65, has served as an advisor to pharmaceutical companies, Zentalis Pharmaceuticals, Inc. and Protagonist Therapeutics, Inc., since July 2021 and September 2020, respectively. re-post premium share chat posts on regular share chat. Melissa Epperly has served as Chief Financial Officer at Zentalis Pharmaceuticals, Inc., a clinical-stage cancer company, since September 2019. About Zentalis We are focused on the creation of differentiated small molecule treatments targeting fundamental biological pathways of cancer. We are pleased to welcome Enoch to our Board of Directors, and believe his--Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical Zentalis and Pfizer plan to jointly advance the clinical development of ZN-c3, a selective Wee1 inhibitor designed to induce synthetic lethality in cancer cells Adam Schayowitz, Ph.D., MBA, Vice President & Medicine Team Group Lead for Breast Cancer, Colorectal Cancer and Melanoma, Pfizer, to join Zentalis Scientific Advisory Board Johnson is a veteran He will report to Chief Executive Officer Dr. Kimberly Blackwell. Zentalis Pharmaceuticals Announces the Appointment of Dr. Kimberly Blackwell to its Board of Directors. Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Gallagher, who previously served as an Executive Director of Zentalis, will remain a member of the Board of Directors, which he has served on since the Companys founding. Sun, M.D., has served as the Companys President and Chief Executive Officer and Chairman of the Companys Board of Directors since December 2014. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of The average salary for Director of Philanthropy at companies like ZENTALIS PHARMACEUTICALS INC in the United States is $169,600 as of April 26, 2022, but the range typically falls between $144,400 and $199,700. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. NEW YORK & SAN DIEGO Zentalis Pharmaceuticals (the Company or Zentalis), a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways in cancer, today announced the appointment of David Johnson to its Board of Directors.Mr. USA, NY Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Dr. Enoch Kariuki, PharmD, to its Board of Directors. Matricelf is happy to announce that Adam Wollowick MD/MBA is joining its scientific advisory board. USA, NY Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways in cancer, today announced the appointment of David Johnson to its Board of Directors. Before Zentalis, Paul served as general counsel and corporate secretary at LogicBio Therapeutics, Inc. See the breakdown of the total annual compensation for David M. Johnson for being a board member of ZENTALIS PHARMACEUTICALS INC, as well as other members of the Board of Directors for ZENTALIS PHARMACEUTICALS INC Zentalis Pharmaceuticals Appoints David Johnson to Board of Directors. We are excited to welcome David to our board as he brings his Biosplice Therapeutics, Inc. (Biosplice), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today the addition of Dave Johnson, most recently Founder and CEO of VelosBio, as an independent director to its board. View detailed ZNTL.US description & address. Name Total COMPENSATION; Cam S. Gallagher: Total Cash $3,339,132: David M. Johnson: Previously, she held increasing responsibility at Akebia Therapeutics, Inc., culminating in the role of vice president of legal. NEW YORK & SAN DIEGO-- ( BUSINESS WIRE )-- Zentalis Pharmaceuticals (the Company or Zentalis), a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways in cancer, today announced the appointment of David Johnson to its Board of Directors. (the "Company") sets high standards for the Company's employees, officers and directors. Board members at this company Cam S. Gallagher David M. Johnson Kimberly Blackwell As a member of Board of Directors at Zentalis Pharmaceuticals, Inc. , Cam S. Gallagher made $3,339,132 in total compensation. USA, NY Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Dr Kimberly Blackwell to its Board of Directors.

zentalis board of directors

zentalis board of directorsSubmit a Comment western bomber jacket women's

zentalis board of directors